Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation

被引:42
|
作者
Lum, Deirdre A. [1 ]
Sokol, Eric R. [1 ]
Berek, Jonathan S. [1 ]
Schulkin, Jay [2 ]
Chen, Ling [3 ]
McElwain, Cora-Ann [2 ]
Wright, Jason D. [3 ]
机构
[1] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[2] Amer Coll Obstetricians & Gynecologists, 409 12th St SW, Washington, DC 20024 USA
[3] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
American College of Obstetricians and Gynecologists; American Association of Gynecologic Laparoscopists; Food and Drug Administration warning; Power morcellation; Survey; OBSTETRICIAN-GYNECOLOGISTS; UTERINE; LEIOMYOSARCOMA; HYSTERECTOMY; LEIOMYOMA; WOMEN;
D O I
10.1016/j.jmig.2016.01.019
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: To determine whether members of the AAGL Advancing Minimally Invasive Gynecologic Surgery Worldwide (AAGL) and members of the American College of Obstetricians and Gynecologists Collaborative Ambulatory Research Network (ACOG CARN) have changed their clinical practice based on the 2014 Food and Drug Administration (FDA) warnings against power morcellation. Design: A survey study. Setting: Participants were invited to complete this online survey (Canadian Task Force classification II-2). Patients: AAGL and ACOG CARN members. Interventions: An online anonymous survey with 24 questions regarding demographics and changes to clinical practice during minimally invasive myomectomies and hysterectomies based on the 2014 FDA warnings against power morcellation. Measurements and Main Results: A total of 615 AAGL members and 54 ACOG CARN members responded (response rates of 8.2% and 60%, respectively). Before the FDA warnings, 85.8% and 86.9%, respectively, were using power morcellation during myomectomies and hysterectomies. After the FDA warnings, 71.1% and 75.8% of respondents reported stopping the use of power morcellation during myomectomies and hysterectomies. The most common reasons cited for discontinuing the use of power morcellation or using it less often were hospital mandate (45.6%), the concern for legal consequences (16.1%), and the April 2014 FDA warning (13.9%). Nearly half of the respondents (45.6%) reported an increase in their rate of laparotomy. Most (80.3%) believed that the 2014 FDA warnings have not led to an improvement in patient outcomes and have led to harming patients (55.1%). Conclusion: AAGL and ACOG CARN respondents reported decreased use of power morcellation during minimally invasive gynecologic surgery after the 2014 FDA warnings, the most common reason cited being hospital mandate. Rates of laparotomy have increased. Most members surveyed believe that the FDA warnings have not improved patient outcomes. (C) 2016 AAGL. All rights reserved.
引用
收藏
页码:548 / 556
页数:9
相关论文
共 50 条
  • [31] FDA Warns Against Power Morcellation for Hysterectomy and Fibroids
    Wallis, Laura
    [J]. AMERICAN JOURNAL OF NURSING, 2014, 114 (07) : 16 - 16
  • [32] Trends in Youth Antidepressant Use and Switching Following US Food and Drug Administration Warnings: A Disparities Analysis
    Carson, Nicholas J.
    Wang, Ye
    Cook, Benjamin L.
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S6 - S7
  • [33] Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration
    Redberg, Rita F.
    Jacoby, Alison F.
    Sharfstein, Joshua M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (04): : 325 - 326
  • [34] US Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Reply
    Parker, William H.
    Kaunitz, Andrew M.
    Pritts, Elizabeth A.
    Olive, David L.
    Chalas, Eva
    Clarke-Pearson, Daniel L.
    Berek, Jonathan S.
    [J]. OBSTETRICS AND GYNECOLOGY, 2016, 127 (05): : 966 - 967
  • [35] Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014
    Moore, Thomas J.
    Furberg, Curt D.
    Mattison, Donald R.
    Cohen, Michael R.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 (06) : 713 - 718
  • [36] An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas
    Parker, William
    Berek, Jonathan S.
    Pritts, Elizabeth
    Olive, David
    Kaunitz, Andrew M.
    Chalas, Eva
    Clarke-Pearson, Daniel
    Goff, Barbara
    Bristow, Robert
    Taylor, Hugh S.
    Farias-Eisner, Robin
    Fader, Amanda Nickles
    Maxwell, G. Larry
    Goodwin, Scott C.
    Love, Susan
    Gibbons, William E.
    Foshag, Leland J.
    Leppert, Phyllis C.
    Norsigian, Judy
    Nager, Charles W.
    Johnson, Timothy
    Guzick, David S.
    As-Sanie, Sawsan
    Paulson, Richard J.
    Farquhar, Cindy
    Bradley, Linda
    Scheib, Stacey A.
    Bilchik, Anton J.
    Rice, Laurel W.
    Dionne, Carla
    Jacoby, Alison
    Ascher-Walsh, Charles
    Kilpatrick, Sarah J.
    Adamson, G. David
    Siedhoff, Matthew
    Israel, Robert
    Paraiso, Marie Fidela
    Frumovitz, Michael M.
    Lurain, John R.
    Al-Hendy, Ayman
    Benrubi, Guy I.
    Raman, Steven S.
    Kho, Rosanne M.
    Anderson, Ted L.
    Reynolds, R. Kevin
    DeLancey, John
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2016, 23 (03) : 303 - 308
  • [37] DRUG ADMINISTRATION AND FOOD
    MACARTHUR, CGC
    [J]. BRITISH MEDICAL JOURNAL, 1979, 1 (6164): : 683 - 683
  • [38] DRUG ADMINISTRATION AND FOOD
    不详
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1979, 1 (6159): : 289 - 289
  • [39] Food and drug administration
    Horton, Linda R.
    [J]. BRITISH MEDICAL JOURNAL, 2007, 334 (7584): : 55 - 56
  • [40] Food and Drug Administration
    Henry, C
    [J]. ANALYTICAL CHEMISTRY, 1999, : 127 - +